Dr. Reddy’s Q3 & 9M FY20 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) PT Raised to INR3,331 at Prabhudas Lilladher
January 28, 2020 5:23 AM ESTPrabhudas Lilladher analyst Surajit Pal raised the price target on Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) to INR3,331.00 (from INR2,910.00) while maintaining a Accumulate (2) rating.
... More